Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TACE plus adebrelimab and apatinib for advanced hepatocellular carcinoma
ChiCTR2400085555Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of adebrelimab and Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Fujian Medical University Cancer Hospital. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
adebrelimabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400085555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085555.